On October On October 8th-10th，the highly anticipated annual event for pharmaceuticals industry — 2019 China Healthcare Summit of Entrepreneurs, Scientists and Investors and Pharmaceutical Achievements Exhibition of the 70th Anniversary of PRC Founding, was grandly held at Beijing Yanqi Lake International Convention & Exhibition Center. The conference commended enterprises that had made extraordinary contributions to the pharmaceuticals industry. China Medical System Holdings Limited (CMS) was conferred three awards, including “Top 10 Listed Companies with the Highest Investment Value in Pharmaceuticals Industry”, “Top 100 Innovative Pharmaceutical Enterprises in China” and “Benchmarking Enterprises in Pharmaceuticals Industry at the 70th Anniversary of PRC Founding”.
2019 China Healthcare Summit of Entrepreneurs, Scientists and Investors was sponsored by China Pharmaceutical Enterprises Association and China Medicinal Biotech Association, and organized by Healthcare Executives and China Healthcare Industry Investment Forum of 50 people (H50). Among the awards won by CMS, “Top 10 Listed Companies with the Highest Investment Value in Pharmaceuticals Industry” has been held for 11 consecutive years and be treated as the vane in the secondary market investment; “Top 100 Innovative Pharmaceutical Enterprises in China” was awarded to top 100 companies representing the first camp of China pharmaceutical enterprises with strong innovation capabilities through in-depth review of their innovation status. The “Benchmarking Enterprises in Pharmaceuticals Industry at the 70th Anniversary of PRC Founding” was awarded to 100 pharmaceutical enterprises that had made extraordinary contributions to social public affairs though rounds of selection voted by 20 authoritative industrial associations.
These three awards are not only the recognition of China’s pharmaceuticals industry for CMS’s investment value, but also the manifestation of the Group’s determination to make continuous endeavor to inject strength into the innovation in China’s pharmaceuticals industry as always. The Group will keep focusing on the innovation research and development as its core strategy to meet the unmet pharmaceutical needs in China market through making deployment of innovative products with different innovation degrees at different development stages and research fields.
